RAPP - Rapport Therapeutics Price-to-Projected Revenue Ratio

Rapport Therapeutics, Inc. (RAPP) focuses on developing CNS drugs, where success depends on regulatory approvals and investment inflows. P/S expectations for the company confirm volatility, with the metric holding around 62.80. The business is not subject to economic cycles, relying instead on scientific breakthroughs. However, early-stage trials and high operating expenses create a risk of rapid capital burn.

Rapport Therapeutics Inc - RAPP Projected Price to Revenue (period 06/08/2024 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Rapport Therapeutics, Inc. (RAPP)

- market price and analyst price targets:

Price Chart Rapport Pharma|RAPP - Price Target Chart

- market capitalization statistics:

Market Value Rapport Corp|RAPP - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Rapport Therapeutics|RAPP - Book Value of Business|Market Cap to Net Assets Ratio rapportrx.com|RAPP - Company Assets

- debt and liquidity data:

- financial results and valuation multiples details:

RAPP - Company Net Income|Expected Profit Rapport Therapeutics, Inc.|RAPP - Company Value to Net Income|Projected Price to Earnings Rapport Pharma|RAPP - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Rapport Therapeutics Inc|RAPP - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Rapport Therapeutics|RAPP - Earnings per share for the last four quarters|Quarterly EPS earnings growth rapportrx.com|RAPP - Earnings per share increase in current year|Earnings growth forecast for next year Rapport Therapeutics, Inc.

- revenue and sales proceeds data:

RAPP - Company Total Revenue|Company Projected Revenue Rapport Pharma|RAPP - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Rapport Therapeutics

Fundamental company analysis:RAPP (Rapport Therapeutics)

Institutional capital evaluates the potential of Rapport Therapeutics, Inc. (RAPP) through the lens of future cash flows. The ratio of market value to projected revenue, reflected in the forward P/S movement, determines the extent of market expectations currently priced in. For this creator of a precision neurotherapy ecosystem, this multiple measures the cost of the right to future sales of innovative drugs. Low metric values confirm the asset is undervalued relative to the prospects of epilepsy treatment.

Direct competitors

Price-to-Projected Revenue Ratio Jazz Pharma JAZZ|Cytokinetics Corp - Price-to-Projected Revenue Ratio|PTCT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scholar Rock|CNTA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Dyne Therapeutics (DYN)|Forward Price-to-Revenue Multiple EWTX|Market Cap to Future Revenue Ratio Alumis Corp ALMS|Forward Price-to-Revenue Multiple ZVRA (Kempharm)|Forward Price-to-Revenue Multiple contineum-tx.com CTNM|Forward P/S Multiple LRMR (larimartx.com)|Forward P/S Multiple Capricor Therapeutics CAPR|TRDA: Forward Price-to-Revenue Multiple|PTHS - Forward P/S Multiple|MNOV: Forward P/S Multiple|Market Cap to Projected Revenue SER|BTAI (BioXcel Therapeutics Inc) - Forward P/S Multiple|ProMIS Neurosciences, Inc. (PMN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple APUS|Price-to-Projected Revenue Ratio AEON (AEON Biopharma, Inc.)|Forward P/S Multiple NLSP (NLS Pharmaceutics Ltd.)|Market Cap to Expected Sales Ratio Bionomics Ltd (BNOX)|HUGE - Price-to-Projected Revenue Ratio|Forward Price to Sales RETA (Reata Pharmaceuticals, Inc.)